Afinitor approved for advanced breast cancer

Afinitor approved for advanced breast cancer

(HealthDay) -- Afinitor (everolimus) has been approved in combination with the drug exemestane to treat postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer, the U.S. Food and Drug Administration said Friday.

The newly approved combination is sanctioned for women whose cancer has progressed or returned despite previous use of the drugs letrozole (Femara) or anastrozole (Arimidex), the agency said in a news release.

Afinitor -- already sanctioned for uses which include treating certain forms of advanced -- was clinically evaluated for the new use among 724 people with . People who took the combination drug had a 4.6-month improvement in the average time to disease progression or death, compared to those who took a placebo.

The most common side effects among those taking Afinitor were mouth ulcers, infection, rash, fatigue, diarrhea, and loss of appetite.

Afinitor is marketed by Novartis, based in East Hanover, N.J.

More information: The National Cancer Institute has more about breast cancer.


add to favorites email to friend print save as pdf

Related Stories

Perjeta approved for advanced breast cancer

Jun 11, 2012

(HealthDay) -- Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in a news release.

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.